1.
Arch Dermatol
; 147(1): 120-2, 2011 Jan.
Article
in English
| MEDLINE
| ID: mdl-21242407
Subject(s)
Eccrine Porocarcinoma/etiology , Graft vs Host Disease/therapy , Papillomavirus Infections/complications , Sweat Gland Neoplasms/etiology , Eccrine Porocarcinoma/virology , Graft vs Host Disease/etiology , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Lymphoma, Mantle-Cell/therapy , Male , Middle Aged , Stem Cell Transplantation/methods , Sweat Gland Neoplasms/virology
2.
J Am Acad Dermatol
; 64(2): 440-1, 2011 Feb.
Article
in English
| MEDLINE
| ID: mdl-21238834
Subject(s)
Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Skin Infections/drug therapy , Staphylococcus aureus/drug effects , Child , Clindamycin/therapeutic use , Drug Resistance, Bacterial , Humans , Microbial Sensitivity Tests , Outpatients , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Vancomycin/therapeutic use
3.
J Drugs Dermatol
; 9(2): 169-71, 2010 Feb.
Article
in English
| MEDLINE
| ID: mdl-20214183
ABSTRACT
Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors. Various dermatologic side effects have been reported, most notably a hand-foot-skin reaction (HFSR). This is a case of a sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. This patient also developed cutaneous squamous cell carcinoma and HFSR in association with sorafenib. To the authors' knowledge, a psoriasiform eruption due to sorafenib has not been reported in the literature and has important therapeutic implications.
